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In this issue of Cell, Takahashi et al. (2007) transfer their seminal work on somatic cell 
reprogramming from the mouse to human. By overexpressing the transcription factor 
quartet of Oct4, Sox2, Klf4, and c-Myc in adult human fibroblasts, they successfully 
isolate human pluripotent stem cells that resemble human embryonic stem cells by all 
measured criteria. This is a significant turning point in nuclear reprogramming research 
with broad implications for generating patient-specific pluripotent stem cells for research 
and therapeutic applications.This year’s three Physiology or Medi-
cine Nobel Laureates—Martin Evans, 
Mario Capecchi, and Oliver Smithies—
will be honored in Stockholm in 10 
days time for their discovery of DNA 
recombination and the development 
of mouse embryonic stem (ES) cell 
technology. It was Martin Evans who 
discovered how to make mouse ES 
cells, enabling any genetic alteration 
to be transferred to the germline and 
hence to the next generation (Evans 
and Kaufman, 1981; Martin, 1981). 
Before this breakthrough, researchers 
studied mouse embryonal carcinoma 
cells derived from tumors, which 
could form every mouse cell lineage 
except the germline. Combining DNA 
recombination and mouse ES cell 
technology revolutionized an entire 
field of research, forming the basis for 
studying and understanding the roles 834 Cell 131, November 30, 2007 ©2007 of numerous genes in embryonic 
development, adult physiology, dis-
ease, and aging. To date, more than 
500 mouse models of human disor-
ders have been generated. Now, with 
the study by Takahashi et al. (2007) 
published in this issue of Cell, another 
important revolution is taking place.
Last summer, Takahashi and 
Yamanaka (2006) stunned the scientific 
community with their study showing 
molecular reprogramming of mouse 
somatic cells into induced pluripotent 
stem (iPS) cells using just four factors: 
Oct4, Sox2, Klf4, and c-Myc. Their 
elegant but demanding approach of 
screening for a cocktail of factors that 
could reprogram mouse fibroblasts 
starting from 24 candidate genes paid 
off with their detailed description of iPS 
cells, which are almost indistinguish-
able from mouse ES cells. As with all Elsevier Inc.scientific discoveries, these exciting 
findings had to be reproduced. Sev-
eral studies published this year not 
only reproduced but also extended 
the Takahashi and Yamanaka findings 
by demonstrating the pluripotency and 
differentiation potential of mouse iPS 
cells in rigorous developmental assays 
(Maherali et al., 2007; Okita et al., 2007; 
Wernig et al., 2007).
In their new study, Takahashi, 
Yamanaka, and their colleagues 
(Takahashi et al., 2007) now translate 
their remarkable findings from mouse 
to human (see Figure 1). They selected 
adult human dermal fibroblasts and 
two other human fibroblast popula-
tions (from synovial tissue and neo-
natal foreskin) from different human 
donors as their reprogramming target 
cell populations. They then trans-
duced the human fibroblast cultures Figure 1. Transcription Factor-Induced Pluripotency
Adult fibroblasts from human donors were exposed to retroviral vectors expressing a cocktail of four transgenes encoding the human factors hOct4, 
hSox2, hKlf4, and hc-Myc (Takahashi et al., 2007). Thirty days after transduction and further cultivation under human ES cell growth conditions, 
human induced pluripotent stem (iPS) cell colonies (among others) that could be propagated and expanded further were isolated. Comparative 
analysis of human iPS cells and human ES cells using assays for morphology, surface-marker expression, gene expression profiling, epigenetic 
status, and in vitro and in vivo differentiation potential revealed a remarkable degree of similarity between these two pluripotent stem cell types.
with retroviral vectors carrying trans-
genes for the human versions of Oct4, 
Sox2, Klf4, and c-Myc and cultured 
the cells under human ES cell culture 
conditions. Thirty days after transduc-
tion, the culture plates were covered 
with human ES cell-like iPS colonies 
(among other colonies), which could 
be further propagated and expanded. 
The retroviral vectors enabled silenc-
ing of all four transgenes after human 
iPS formation (as found in the mouse 
system) indicating that the iPS cells 
are fully reprogrammed and no longer 
depend on transgene expression.
Unlike the mouse study, human 
iPS cells were generated without any 
genetic selection procedures. Given 
the lower mitotic index of human ES 
cells, it is not surprising that the gen-
eration of human iPS cells takes nota-
bly longer than in the mouse system. 
The authors subjected their human 
iPS cells to a panel of assays to com-
pare them with human ES cells. These 
assays included morphological stud-
ies, surface-marker expression, epi-
genetic status, formation of embryoid 
bodies in vitro, directed differentia-
tion into neural cells and beating car-
diomyocytes (according to human 
ES cell differentiation protocols), and 
finally teratoma formation in vivo. 
DNA microarray analysis revealed 
the remarkable degree of similar-
ity between the global gene expres-
sion patterns of human iPS cells and 
human ES cells. Notably, genomic 
DNA analysis as well as analysis of 
short tandem repeats demonstrated 
the genetic origin of independent 
human iPS clones from their parental 
fibroblast populations.
The derivation of mouse and then 
human ES cells (Thomson et al., 1998) 
as the gold standard of pluripotent 
stem cell populations has necessarily 
led to emphasis on differences in the 
regulation of self-renewal between 
mouse and human ES cells. For 
example, human ES cells depend on 
bFGF for self-renewal, whereas their 
mouse counterparts depend on the 
Lif/Stat3 pathway; BMP is involved in 
mouse ES cell self-renewal, whereas 
in human ES cells it induces differen-
tiation. Extrinsic factors and signals 
for maintaining pluripotency may dif-fer between mouse and human. How-
ever, the ability to translate somatic 
cell reprogramming from mouse to 
human using the same transcription 
factor quartet further emphasizes the 
conserved nature of the Oct4/Sox2 
transcription factor network that 
controls self-renewal of mouse and 
human ES cells (Boyer et al., 2005). 
Given that Klf4 and c-Myc are chro-
matin modifiers and can immortal-
ize cells, one might be able to find 
other factors or small molecules that 
could replace these two factors in the 
cocktail (Yamanaka, 2007). In these 
studies, the possibility of retroviral 
insertional mutagenesis, resulting 
in the activation of other genes con-
tributing to reprogramming, cannot 
be excluded, providing an opportu-
nity to potentially identify new repro-
gramming factors beyond the cur-
rent quartet. Also, taking a broader 
screening approach for reprogram-
ming human fibroblasts (as Takahashi 
and Yamanaka did for their mouse 
study) might yield other combinations 
of reprogramming factors.
Direct reprogramming of somatic 
cells to a pluripotent state, thus revers-
ing the developmental arrow of time, 
is considered by some to be the “holy 
grail” of stem cell research. Once the 
results in human cells are confirmed, 
these advances will enable the cre-
ation of patient-specific stem cell lines 
to study different disease mechanisms 
in the laboratory. Such cellular models 
also have the potential to dramatically 
increase the efficiency of drug discov-
ery and to provide valuable tools for 
toxicology testing. Furthermore, this 
reprogramming system could make 
the idea of customized patient-specific 
screening and therapy both possible 
and economically feasible. Finally, the 
work will have a powerful impact on 
the intense debate regarding the moral, 
religious, and political aspects of ES cell 
research. However, a big mistake now 
would be to consider human ES cells 
obsolete. There are still many hurdles 
to overcome before we fully understand 
pluripotency and before we have human 
iPS cells in hand that are suitable for 
therapeutic application. For example, 
a significant proportion of mice derived 
from mouse iPS cells develop tumors Cell 131, Novedue to reactivation of the c-Myc retro-
virus (Okita et al., 2007) compared to 
mice derived from ES cells, which are 
normal. The search is now on to find a 
way to reprogram somatic cells without 
retroviruses and maybe even using a 
cocktail of small molecules. Given this, 
it should be emphasized that human 
ES cell research is more important than 
ever for it will shed light on how iPS 
cells can best be maintained in their 
pluripotent state and how they can be 
induced to differentiate into the cell 
lineage of interest. The field of nuclear 
reprogramming has come a long way 
from the initial nuclear transplantation 
studies in frogs 50 years ago, to the 
birth of Dolly, the first mammal cloned 
from adult somatic cells (Wilmut et al., 
1997), to the fallout from the fabricated 
human nuclear transfer experiments 
of several years ago, to the landmark 
studies of Takahashi, Yamanaka, and 
their colleagues, first in mice and now 
in humans.
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